Pathologic Myopia

• EMA approval · 2026-01-09
  EMA Authorised: Rimmyrah (ranibizumab) — Qilu Pharma Spain S.L.

  EMA authorised Rimmyrah (ranibizumab) for several ocular indications including wet age-related macular degeneration and macular edema; decis…

• EMA approval · 2025-12-17
  EMA Authorised: Lucentis (ranibizumab) — Novartis Europharm Limited

  EMA authorised Lucentis (ranibizumab) for multiple ophthalmic indications including wet age-related macular degeneration, macular edema, dia…

• FDA approval · 2014-05-06
  FDA Approved: VISUDYNE — Supplemental Application (Bausch & Lomb Incorporated)

  FDA approved a supplemental application for VISUDYNE (verteporfin for injection) filed by Bausch & Lomb Incorporated.

• FDA approval · 2013-10-08
  FDA Approved: VISUDYNE — Supplemental Application (Bausch & Lomb Incorporated)

  FDA approved a supplemental application for Visudyne (verteporfin for injection) filed by Bausch & Lomb Incorporated.